language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
OFIXOFIX

$13.53

+0.36
arrow_drop_up2.73%
Market closed·update27 Feb 2026 21:00

$13.5

-0.03
arrow_drop_down0.22%
Post-market·update27 Feb 2026 23:41
Day's Range
13.35-14.22
52-week Range
10.24-18.66

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-24
Next Earnings TimeBefore Market Open
Volume326.81K
Average Volume 30d229.63K

AI OFIX Summary

Powered by LiveAI
💰
-4
Valuation (P/E Ratio)
Negative P/E indicates losses, making traditional valuation difficult.
📈
N/A
EPS Growth (YoY)
EPS is negative, year-over-year growth is not applicable.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Neutral
70

Orthofix Medical Inc. exhibits mixed performance. Fundamentally, the company is navigating challenges with negative earnings and free cash flow, though revenue has shown some recent growth. Thematic alignment with medical technology is positive. Technical indicators show some bullish signs in the short term but also overbought conditions.

Positive

Thematic

75

Orthofix operates in the medical technology sector, which generally benefits from aging populations, increased healthcare spending, and technological advancements. The company's focus on spine and orthopedic solutions places it within a growing market segment.

Mixed

Fundamental

60

Financially, Orthofix has shown negative earnings and free cash flow in recent periods, indicating profitability challenges. While revenue has seen some quarterly increases, sustained profitability and positive cash generation are key areas for improvement.

Bullish/Neutral

Technical

70

Short-term technical indicators suggest a cautiously bullish stance. The stock has seen recent price appreciation, with many moving averages indicating a buy signal. However, some oscillators are in overbought territory, hinting at potential consolidation.

FactorScore
Healthcare Sector Growth80
Innovation in Medical Devices75
Regulatory Landscape60
Competition65
FactorScore
Valuation70
Profitability20
Growth70
Balance Sheet Health60
Cash Flow25
FactorScore
Trend Analysis80
Momentum55
Volume Confirmation65
Support & Resistance60

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (5)

Earnings Performance chevron_right

Positive Earnings Surprises

The company has consistently beaten EPS estimates in the last several quarters (e.g., Q2 2025 estimate -0.27 vs. reported -0.08, surprise 70.0%; Q1 2025 estimate -0.05 vs. reported 0.01, surprise 120.0%). This demonstrates an ability to manage operations effectively and exceed market expectations.

Financial Health & Liquidity chevron_right

Improving Cash Position and Reduced Debt

While Q4 2024 shows higher debt than Q4 2023, the operating cash flow for Q4 2024 turned positive ($23.73M) compared to negative in Q4 2023 (-$45.75M). The end cash position has also improved to $85.74M in Q4 2024 from $37.76M in Q4 2023.

Show More 🔒
thumb_down

Bearish Points (7)

Earnings Performance chevron_right

Consistent Net Losses and Negative EPS

The company has consistently reported negative net income and EPS (e.g., TTM net income of -$109.63M, EPS of -3.7). This indicates ongoing operational losses and a lack of profitability, posing a significant risk to investors.

Financial Health & Debt chevron_right

Increasing Debt and Negative Free Cash Flow

Total debt has increased from $117.07M in Q4 2023 to $179.63M in Q4 2024. Furthermore, free cash flow has been negative for multiple periods (e.g., -$9.09M in Q4 2024, -$107.80M in Q4 2023), signaling potential cash burn and funding challenges.

Show More 🔒

Calendar

August 2025

5

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.04

A: $0.04

L: $0.04

H: 199.87M

A: 196.89M

L: 196.00M

Profile

Employees (FY)1.62K
ISINUS68752M1080
FIGI-

Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and provides 7D flash navigation system for spine and cranial procedures. Its Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Seasonals

2025
2024
2023
2022
2021

Price Target

22.30 USD

The 39 analysts offering 1 year price forecasts for OFIX have a max estimate of 27.20 and a min estimate of 16.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
38.6M (98.54%)
Closely held shares
572K (1.46%)
39.2M
Free Float shares
38.6M (98.54%)
Closely held shares
572K (1.46%)

Capital Structure

Market cap
442.74M
Debt
179.63M
Minority interest
0.00
Cash & equivalents
83.24M
Enterprise value
539.13M

Valuation - Summary

Market Cap
443M
Net income
-110M(-24.76%)
Revenue
606M(136.85%)
443M
Market Cap
443M
Net income
-110M(-24.76%)
Revenue
606M(136.85%)
Price to earning ratio (P/E)-4.00x
Price to sales ratio (P/S)0.70x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
799.49M
COGS
253.61M
Gross Profit
545.88M
OpEx
623.6M
Operating Income
-77.72M
Other & Taxes
48.28M
Net Income
-126M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒